Elagolix

Generic Name
Elagolix
Brand Names
Oriahnn 28 Day Kit, Orilissa
Drug Type
Small Molecule
Chemical Formula
C32H30F5N3O5
CAS Number
834153-87-6
Unique Ingredient Identifier
5B2546MB5Z
Background

Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasin...

Indication

用于治疗子宫内膜异位症并伴有中度至重度疼痛。

Associated Conditions
Heavy Menstrual Bleeding, Moderate to severe pain
Associated Therapies
-
Clinical Trials
Related News

Brain Blood Flow Responses to Stress: Sex Differences

First Posted Date
2024-02-12
Last Posted Date
2024-04-23
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
26
Registration Number
NCT06253702
Locations
🇺🇸

University of Wisconsin, Madison, Wisconsin, United States

A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain

Phase 3
Recruiting
Conditions
Endometriosis
Interventions
Drug: Elagolix placebo
Drug: Elagolix
First Posted Date
2023-10-10
Last Posted Date
2023-10-10
Lead Sponsor
Nanjing Chia-tai Tianqing Pharmaceutical
Target Recruit Count
330
Registration Number
NCT06076486
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain

Phase 3
Recruiting
Conditions
Endometriosis
Interventions
Drug: Elagolix placebo
Drug: Elagolix
First Posted Date
2022-12-13
Last Posted Date
2022-12-13
Lead Sponsor
Qilu Pharmaceutical (Hainan) Co., Ltd.
Target Recruit Count
336
Registration Number
NCT05648669
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

Phase 4
Recruiting
Conditions
Mild Autonomous Cortisol Excess
Interventions
Drug: Elagolix
First Posted Date
2021-09-09
Last Posted Date
2023-07-27
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
12
Registration Number
NCT05038878
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb

Phase 2
Terminated
Conditions
Endometriosis
Interventions
Drug: BAY1817080
Drug: Placebo
Drug: Elagolix
First Posted Date
2020-11-03
Last Posted Date
2023-08-01
Lead Sponsor
Bayer
Target Recruit Count
215
Registration Number
NCT04614246
Locations
🇺🇸

Physician Care Clinical Research, Sarasota, Florida, United States

🇺🇸

Medisense, Inc., Atlanta, Georgia, United States

🇺🇸

HWC Women's Research Center, Englewood, Ohio, United States

and more 141 locations

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

First Posted Date
2020-04-03
Last Posted Date
2024-12-20
Lead Sponsor
AbbVie
Target Recruit Count
800
Registration Number
NCT04333576
Locations
🇺🇸

Wright State Physicians Health Center /ID# 217272, Fairborn, Ohio, United States

🇺🇸

Pinnacle Research Group /ID# 217062, Anniston, Alabama, United States

🇺🇸

ACCEL Research Sites /ID# 218044, Birmingham, Alabama, United States

and more 176 locations

Elagolix for Fertility Enhancement Clinical Trial

First Posted Date
2019-07-31
Last Posted Date
2024-07-26
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
10
Registration Number
NCT04039204
Locations
🇺🇸

Wake Forest Univesity Health Sciences, Winston-Salem, North Carolina, United States

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

Phase 2
Completed
Conditions
Polycystic Ovary Syndrome
Interventions
Drug: Elagolix
Drug: Placebo
First Posted Date
2019-05-15
Last Posted Date
2022-06-08
Lead Sponsor
AbbVie
Target Recruit Count
118
Registration Number
NCT03951077
Locations
🇺🇸

Thomas Jefferson University /ID# 205614, Philadelphia, Pennsylvania, United States

🇺🇸

University of Texas (UT) Health Women's Research Center at Memorial City /ID# 216266, Houston, Texas, United States

🇺🇸

Advances in Health, Inc. /ID# 211249, Houston, Texas, United States

and more 51 locations

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Phase 4
Completed
Conditions
Uterine Fibroids
Interventions
Drug: Placebo
Drug: Elagolix
First Posted Date
2019-03-22
Last Posted Date
2022-03-31
Lead Sponsor
AbbVie
Target Recruit Count
82
Registration Number
NCT03886220
Locations
🇺🇸

Johns Hopkins University /ID# 211135, Baltimore, Maryland, United States

🇺🇸

Caceres Specialized Gynecology /ID# 214956, Kissimmee, Florida, United States

🇺🇸

Georgia Research for Women /ID# 211321, Atlanta, Georgia, United States

and more 45 locations

Cardiovascular Disease Risk in Women With Endometriosis

Early Phase 1
Recruiting
Conditions
Endometriosis
Interventions
Drug: Elagolix
First Posted Date
2018-11-19
Last Posted Date
2024-11-06
Lead Sponsor
Yale University
Target Recruit Count
17
Registration Number
NCT03746535
Locations
🇺🇸

John B Pierce Laboratory, New Haven, Connecticut, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy